RS Negrin, DH Haeuber, A Nagler, LC Olds, … - Annals of internal …, 1989 - Am Coll Physicians Design: The G-CSF was administered by daily subcutaneous injection to outpatients in a phase
I-II trial. Dose was escalated every 2 weeks between 0.1 to 3.0 µg/kg body weight d over an
8-week treatment period. ... Setting: Outpatient clinical research center at a university ... Cited by 155 - Related articles - All 3 versions
- ►hematologylibrary.org [PDF] A Ganser, B Volkers, J Greher, OG Ottmann, … - …, 1989 - bloodjournal.hematologylibrary.org . Hematology; all rights reserved Copyright 2007 by The American Society of DC 20036. by the
American Society of Hematology, 1900 M St, NW, Suite 200, Washington Blood (print ISSN
0006-4971, online ISSN 1528-0020), is published semimonthly ... For personal use only. ... Cited by 163 - Related articles - All 9 versions
- ►hematologylibrary.org [PDF] JH Antin, BR Smith, W Holmes, DS … - Blood, 1988 - bloodjournal.hematologylibrary.org . Hematology; all rights reserved Copyright 2007 by The American Society of DC 20036. by the
American Society of Hematology, 1900 M St, NW, Suite 200, Washington Blood (print ISSN
0006-4971, online ISSN 1528-0020), is published semimonthly ... For personal use only. ... Cited by 172 - Related articles - All 5 versions
Y Kobayashi, T Okabe, K Ozawa, S Chiba, M Hino, … - The American journal of …, 1989 - Elsevier Treatment of Myelodysplastic Syndromes with Recombinant Human Granulocyte Colony-Stimulating
Factor: A Preliminary Report YUKIO KOBAYASHI, MD, TETSURO OKABE, MD, DMS, KEIYA
OZAWA, MD, DMS, SHIGERU CHIBA, MD, MASAYUKI HINO, MD, KOHEI MIYAZONO, ... Cited by 71 - Related articles - All 3 versions
- ►bloodjournal.org [PDF] RS Negrin, DH Haeuber, A Nagler, Y Kobayashi, J … - Blood, 1990 - Am Soc Hematology . reserved Hematology; all rights Copyright 2007 by The American Society of Suite 200, Washington
DC 20036. semimonthly by the American Society of Hematology, 1900 M St, NW, Blood (print
ISSN 0006-4971, online ISSN 1528-0020), is published ... For personal use only. at ... Cited by 173 - Related articles - All 3 versions
S Vadhan-Raj, M Keating, A LeMaistre, WN … - New England Journal …, 1987 - content.nejm.org The myelodysplastic syndromes are characterized by ineffective hematopoiesis and refractory
cytopenias. In an attempt to improve hematopoiesis, we administered recombinant human
granulocyte--macrophage colony-stimulating factor (GM-CSF) to eight patients with ... Cited by 390 - Related articles - All 4 versions
Y Yoshida, K Hirashima, S Asano, F Takaku - Br J Haematol, 1991 - interscience.wiley.com Summary.We conducted a phase II study of the intravenous administration of a glycosylated
recombinant human granulocyte colony-stimulating factor (rhG-CSF) for 7–14 d in 41 patients
with the myelodysplastic syndromes (MDS). Administration of rhG-CSF elicited striking ... Cited by 80 - Related articles - All 3 versions
- ►bloodjournal.org [PDF] HP Koeffler, D Heitjan, R Mertelsmann, JE Kolitz, P … - Blood, 1988 - Am Soc Hematology . Hematology; all rights reserved Copyright 2007 by The American Society of DC 20036. by the
American Society of Hematology, 1900 M St, NW, Suite 200, Washington Blood (print ISSN
0006-4971, online ISSN 1528-0020), is published semimonthly ... For personal use only. ... Cited by 98 - Related articles - All 4 versions
- ►ascopubs.org [PDF] JA Thompson, DJ Lee, P Kidd, E Rubin, J … - Journal of Clinical …, 1989 - jco.ascopubs.org The toxicity, pharmacokinetics, and hematologic effects of granulocyte-macrophage colony-stimulating
(GM-CSF) were studied in a phase 1/11 trial of 16 patients with myelodysplastic syndrome
(MDS). The GM-CSF was administered subcutaneously (SC) daily so as to achieve ... Cited by 113 - Related articles - All 6 versions
- ►hematologylibrary.org [PDF] A Ganser, G Seipelt, A Lindemann, OG … - …, 1990 - bloodjournal.hematologylibrary.org YELODYSPLASTIC syndromes (MDS) are charac- M terized by progressive refractory cytopenias
with ... METHODS In a phase 1-11 study, nine patients with MDS and transfusion-dependent
cytopenia were treated with rhIL-3: three men and six women, ranging in age from 32 to ... Cited by 145 - Related articles - All 3 versions
